Adial pharmaceuticals reports 2023 fiscal year financial results and provides business update

Received favorable feedback from us and eu regulatory agencies advancing discussions with potential strategic partners received $4.3 million in gross proceeds from warrant exercises subsequent to year-end 2023 glen allen, va., april 02, 2024 (globe newswire) -- adial pharmaceuticals, inc. (nasdaq: adil; adilw) (“adial” or the “company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2023 fiscal year ended december 31, 2023.
ADIL Ratings Summary
ADIL Quant Ranking